Table 6.

Combined targeting of angiogenesis and inflammation: patients with progressive disease

Tumor type	No. of patients	Targeted (nuclear) transcription factors	Progressive disease No. of patients (%)
Sarcomas I	21	PPAR α/γ, PPAR δ	4 (19)
Angiosarcoma	6	PPAR α/γ, PPAR δ	0
Melanoma I	19	PPAR α/γ, PPAR δ	4 (21)
Melanoma II Arm B	35	PPAR α/γ, PPAR δ	6 (17)
Langerhans’ cell histiocytosis	2	PPAR α/γ, PPAR δ	0
Renal clear cell carcinoma I	18	PPAR α/γ, PPAR δ	9 (50)
Renal clear cell carcinoma II	33	PPAR α/γ PPAR δ via IFN-α receptor	2 (7)
Hormone-refractory prostate cancer	36	PPAR α/γ, PPAR δ glucocorticoid receptor	5 (14)
Cholangiocellular carcinoma	21	PPAR α/γ, PPAR δ	0

Receptor ligands: PPAR α/γ agonist, PPARδ antagonist (COX-2 inhibitor), dexamethasone, interferon-alpha

PPAR peroxisome proliferator-activated receptor